Finding the right dose of fulvestrant in breast cancer.

Estevez L, Alvarez I, Tusquets I, Segui MA, Munoz M, Fernandez Y, Lluch A.

Cancer Treat. Rev. 2013; 39: 136-141. FI: 6.024 (Q1).

SEOM clinical guidelines for the management of metastatic breast cancer 2013.

Llombart-Cussac A, de la Haba J, Ruiz A, Alvarez I, Cortes J.

Clin. Transl. Oncol. 2013; 15: 1004-1010. FI: 1.276 (Q4).

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Alvarez Lopez I, Dorca J, Martinez S, Batista Lopez N, Dominguez Fernandez S, Cuyas E, Visa J, Rodriguez-Gallego E, Quirantes-Pine R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA, Metten 10 Investigators.

Oncotarget. 2013; 4: 1484-1495. FI: 6.636 (Q1).

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.

Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, Margeli Vila M, Anton A, Rodriguez-Lescure A, Segui-Palmer MA, Munoz-Mateu M, Dorca Ribugent J, Lopez-Vega JM, Jara C, Espinosa E, Mendiola Fernandez C, Andres R, Ribelles N, Plazaola A, Sanchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacon JI, Rodriguez CA, Hernando B, Alvarez I, Carrasco E, Lluch A.

J. Clin. Oncol. 2013; 31: 2593-2599. FI: 18.038 (Q1).

Survey of the Perceived Quality of Patient Care in a Radiation Oncology Service: Results From 2002-2011.

Eguiguren Bastida M, Minguez J, Blanco C, Urraca J, Querejeta A, Uranga I, Ciria J, Rodríguez G, Caffiero S, Guimon E. A.

Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 541-0. FI: 4.105 (Q1).

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial.

Llombart-Cussac A, Ruiz A, Anton A, Barnadas A, Antolin S, Ales-Martínez JE, Álvarez I, Andres R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M.

Cancer. 2012; 118: 241-247. FI: 4.771 (Q1).

New imaging and molecular biomarkers to predict pathological response to bevacizumab-based treatment in neoadjuvant breast cancer.

García-Foncillas J, Plazaola A, Hernando B, Sánchez R, Álvarez I, Anton A, Martínez Del Prado P, Llombart A, Sherer S, López-vega jm.

Ann. oncol. 2012; 23: 82-83. FI: 6.425 (Q1).

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers.

Bastien RRL, Rodríguez-Lescure A, Ebbert MTW, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Segui MA, Barley, Lee B, Kenneth M, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med. Genomics. 2012; 5: -0. FI: 3.693 (Q2).